Tissue Regenix (GB:TRX) has released an update.
Tissue Regenix Group PLC has announced the issuance of 821,167 new ordinary shares following the exercise of share options by senior employees, including the CEO and CFO, under the Company’s Long-Term Incentive Plan. The shares were sold to cover the costs associated with the options exercise, and the new shares are expected to begin trading on the AIM market. Post-admission, the total number of voting rights in Tissue Regenix will be 71,395,635 ordinary shares.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
